Aims Activating mutations in the gene encoding epidermal growth factor receptor (EGFR)
can confer sensitivity to EGFR tyrosine kinase inhibitors such as gefitinib in patients with …

Lung cancer is the leading cause of cancer death worldwide. Molecular targeted therapy
has greatly advanced the field of treatment for non-small cell lung cancer (NSCLC), which …

Context.—In 2013, an evidence-based guideline was published by the College of American
Pathologists, the International Association for the Study of Lung Cancer, and the Association …

Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …

Selection of lung cancer patients for therapy with tyrosine kinase inhibitors directed at EGFR
requires the identification of specific EGFR mutations. In most patients with advanced …

Recent advances in the treatment of non-small cell lung cancer (NSCLC) with new agents
require accurate histological subtyping at diagnosis to avoid the higher risk of an adverse …

Numerous studies have demonstrated the suitability of cytology specimens for molecular
analysis. When combined with the ability to acquire tissue in a minimally invasive manner …

Purpose We aimed to evaluate the distribution of individual epidermal growth factor receptor
(EGFR) mutation subtypes found in routine cytological specimens. Patients and methods A …

Objectives We previously reported low expression of miR-375 in squamous-cell carcinoma
(SCC) and high expression in adenocarcinoma (AC) of the lung. miR-375's target genes and …

Background Though the possibility of using malignant pleural effusions (MPEs) as
alternatives for metastatic pleural tumor tissues (MPTTs) in epidermal growth factor receptor …